Pharma Industry News Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy 1 week agoAdd Commentby David Miller946 Views SEGRAM aims to offer an alternative to glucocorticoid‑based treatment Source: PharmaTimes